Sung Ji Nam is a Director and Life Science and Diagnostic Tools Analyst at BTIG. She provides comprehensive coverage of the life science and diagnostic tools sector. Prior to BTIG, Ms. Nam was a Senior Analyst within Equity Research at Avondale Partners. She held similar roles at Cantor Fitzgerald and Gleacher & Company, where she was named an All-America Research Team Rising Star by Institutional Investor in 2011. Ms. Nam began her career in equity research at JP Morgan, covering life science tools, diagnostics, small to mid-cap medical technology and pharmaceutical services companies. Previously, she was a Senior Program Officer of Science, Higher Education and Healthcare at the Gordon and Betty Moore Foundation. Earlier in her career, Ms. Nam was a Financial Analyst within the Healthcare Corporate Finance Group at Robertson Stephens. She holds a BA in chemistry and an MBA, both from Harvard University.
Coverage Area
| Company | Ticker |
|---|---|
| Fulgent Genetics | FLGT |
| Bruker Corporation | BRKR |
| Castle Biosciences, Inc. | CSTL |
| Fluidigm Corporation | FLDM |
| GenMark Diagnostics, Inc. | GNMK |
| Illumina, Inc. | ILMN |
| Luminex Corporation | LMNX |
| Myriad Genetics, Inc. | MYGN |
| Oxford Immunotec Global PLC | OXFD |
| Quotient Ltd. | QTNT |
| Quanterix Corporation | QTRX |
| Thermo Fisher Scientific, Inc. | TMO |
| Veracyte, Inc. | VCYT |
| Waters Corporation | WAT |
| Centogene | CNTG |
| Guardant Health | GH |
| CareDx | CDNA |
| Genetron Holdings | GTH |